Device makers release a flurry of studies at European conference

Most of the major players in the medical device arena, and a few from off the bench, are busy touting new products
and results from a slew of clinical trials at the European Assn. of
Percutaneous Cardiovascular Interventions annual conference, EuroPCR 2010:

Abbott (NYSE:ABT):

New Data Reinforces Safety Profile of
Abbott’s Market-Leading XIENCE V Drug Eluting Stent:

In XIENCE V USA Study, XIENCE V Demonstrates Low Blood Clot Rate
at One Year in Real-World Patient Population;

In SPIRIT V Diabetes Trial, XIENCE V Demonstrates Zero Cases of
Stent Thrombosis at One Year in Patients with Diabetes
Abbott’s Investigational MitraClip
System Demonstrates Strong Safety Results and Improved Clinical
Outcomes for Common Causes of Leaky Heart Valves:

Preliminary Results Also Show MitraClip Device Maintains
Durability through Two Years in Patients Treated for Mitral
Regurgitation
Abbott’s Groundbreaking Bioresorbable
Technology Continues to Demonstrate Exceptional Clinical
Results:

New Six-Month Data on Abbott’s Bioresorbable Vascular Scaffold
Reinforces Its Potential to Be the Next Revolution in
Interventional Cardiology

Abiomed Inc. (NSDQ:ABMD):

Abiomed Reports Updated USpella Results
Presented at EuroPCR 2010:

52% of patients improved New York Heart Association (NYHA)
classification by one or more categories after Impella-supported
complex PCI. Prior to treatment, 63% of patients were in NYHA class
three or four. After treatment, 70% were in NYHA class one or
two.

Cordis Corp. [Johnson & Johnson
(NYSE:JNJ)]:

NEVO Sirolimus-Eluting Coronary Stent
Continues to Demonstrate Excellent Safety and Efficacy Outcomes in
New Twelve-Month Data:

NEVO, Incorporating RES TECHNOLOGY, Continues to Support Excellent
Safety and Efficacy Outcomes vs. the Taxus Liberte According to
Data Presented at EuroPCR 2010

InspireMD Ltd.:

InspireMD Will Provide a Sneak
Preview of the Next Generation MGuard Prime, a State of the Art Net
Protective Cobalt Chromium Stent System:

InspireMD is Also Proud to Announce That MGuard is Now Available
With an Improved Delivery System. Final 6 Month Results of the
MAGICAL Trial and Final 1 Year Results of the INSPIRE Study Will be
Presented During EuroPCR 2010

Medtronic Inc. (NYSE:MDT):

Medtronic CoreValve System Shows
Long-Term Efficacy and Durability in Pivotal Trial:

Market-Leading Transcatheter Aortic Valve Delivers Positive
Clinical Outcomes Through Two Years in Major International Study;
Achieves 10,000-patient Milestone
Multiple European Clinical Registries
Show Important Benefits of Medtronic CoreValve Transcatheter Aortic
Valve System:

Data Demonstrates That Revolutionary Treatment for Patients with
Diseased Heart Valves Is Transitioning Successfully into Standard
Clinical Practice throughout Europe
Medtronics Resolute Drug-Eluting Stent
Matches Market-Leading Rival in Large Head-to-Head Study:

One-Year Clinical Results from Innovative RESOLUTE All Comers Trial
Show Excellent Performance for Resolute DES in Challenging Patient
Population

NMT Medical Inc. (NSDQ:NMTI):

NMT Medical Launches Rapid Transport
Septal Implant Delivery System in France:

Enhancement Allows Easier Implantation of BioSTAR and STARFlex
Devices

NovoStent Corp.:

NovoStent Announces 6-Month
Results of SAMBA Femoropopliteal Trial:

The SAMBA data showed a 97% Freedom from Target Lesion
Revascularization rate. There were no device related complications
in any of the 38 patients treated in the trial.

OrbusNeich:

Data Presented at EuroPCR 2010
Demonstrate Effectiveness of OrbusNeich’s Genous” Bio-engineered R
stent” in Diabetic Patients:

OrbusNeich today announced that 12-month follow-up data from a
subset analysis of the global e-HEALING registry demonstrate that
the company’s Genous Bio-engineered R stent is effective in
diabetic patients.

St. Jude Medical Inc. (NYSE:STJ):

St. Jude Medical Announces Initiation of
a Study to Evaluate the Economic Impact of FFR in Europe and
Canada:

Country-specific analysis will evaluate the cost effectiveness of
an FFR-guided intervention strategy for patients with multivessel
coronary artery disease in the UK, Germany, France, Italy,
Switzerland, Belgium and Canada; Unique data from each country will
be used to assess the budget and health impact of FFR on its health
care system

Tryton Medical Inc.: